Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 12 studies | 26% ± 8% | |
intestine | 5 studies | 24% ± 11% | |
kidney | 4 studies | 17% ± 1% | |
peripheral blood | 4 studies | 20% ± 3% | |
pancreas | 3 studies | 34% ± 4% | |
uterus | 3 studies | 27% ± 7% | |
breast | 3 studies | 20% ± 3% | |
placenta | 3 studies | 19% ± 2% | |
liver | 3 studies | 20% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 11046.27 | 1445 / 1445 | 100% | 122.24 | 183 / 183 |
liver | 100% | 10290.43 | 226 / 226 | 100% | 98.52 | 406 / 406 |
lung | 100% | 14191.52 | 578 / 578 | 100% | 142.92 | 1155 / 1155 |
ovary | 100% | 9200.76 | 180 / 180 | 100% | 140.03 | 430 / 430 |
intestine | 100% | 11237.13 | 966 / 966 | 100% | 98.44 | 526 / 527 |
prostate | 100% | 9901.25 | 245 / 245 | 100% | 84.58 | 501 / 502 |
uterus | 100% | 12155.18 | 170 / 170 | 100% | 134.97 | 458 / 459 |
breast | 100% | 13251.65 | 459 / 459 | 100% | 112.06 | 1115 / 1118 |
stomach | 100% | 7395.82 | 359 / 359 | 100% | 99.18 | 285 / 286 |
thymus | 100% | 11247.23 | 652 / 653 | 100% | 136.42 | 603 / 605 |
skin | 100% | 11213.26 | 1809 / 1809 | 99% | 99.59 | 468 / 472 |
bladder | 100% | 12484.43 | 21 / 21 | 99% | 140.57 | 499 / 504 |
kidney | 100% | 9107.33 | 89 / 89 | 99% | 134.08 | 889 / 901 |
adrenal gland | 100% | 13654.88 | 258 / 258 | 96% | 69.99 | 221 / 230 |
pancreas | 86% | 3287.78 | 281 / 328 | 99% | 150.74 | 176 / 178 |
brain | 36% | 1157.98 | 962 / 2642 | 91% | 83.36 | 644 / 705 |
adipose | 100% | 15657.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 11808.11 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 113.51 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 80.01 | 1 / 1 |
blood vessel | 100% | 11635.18 | 1334 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 56.43 | 78 / 80 |
heart | 97% | 5310.77 | 831 / 861 | 0% | 0 | 0 / 0 |
muscle | 96% | 5792.08 | 769 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 44.25 | 27 / 29 |
peripheral blood | 86% | 17598.40 | 801 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042531 | Biological process | positive regulation of tyrosine phosphorylation of STAT protein |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0072659 | Biological process | protein localization to plasma membrane |
GO_0006954 | Biological process | inflammatory response |
GO_0071260 | Biological process | cellular response to mechanical stimulus |
GO_1905038 | Biological process | regulation of membrane lipid metabolic process |
GO_0008625 | Biological process | extrinsic apoptotic signaling pathway via death domain receptors |
GO_0010803 | Biological process | regulation of tumor necrosis factor-mediated signaling pathway |
GO_0003332 | Biological process | negative regulation of extracellular matrix constituent secretion |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_1902339 | Biological process | positive regulation of apoptotic process involved in morphogenesis |
GO_0008630 | Biological process | intrinsic apoptotic signaling pathway in response to DNA damage |
GO_0003176 | Biological process | aortic valve development |
GO_0006693 | Biological process | prostaglandin metabolic process |
GO_0042742 | Biological process | defense response to bacterium |
GO_0003177 | Biological process | pulmonary valve development |
GO_0050729 | Biological process | positive regulation of inflammatory response |
GO_0034250 | Biological process | positive regulation of amide metabolic process |
GO_1903140 | Biological process | regulation of establishment of endothelial barrier |
GO_0045834 | Biological process | positive regulation of lipid metabolic process |
GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
GO_1900119 | Biological process | positive regulation of execution phase of apoptosis |
GO_0010614 | Biological process | negative regulation of cardiac muscle hypertrophy |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0002947 | Cellular component | tumor necrosis factor receptor superfamily complex |
GO_0005615 | Cellular component | extracellular space |
GO_0043235 | Cellular component | receptor complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0045121 | Cellular component | membrane raft |
GO_0016020 | Cellular component | membrane |
GO_0009986 | Cellular component | cell surface |
GO_0000139 | Cellular component | Golgi membrane |
GO_0043120 | Molecular function | tumor necrosis factor binding |
GO_0005031 | Molecular function | tumor necrosis factor receptor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TNFRSF1A |
Protein name | Tumor necrosis factor receptor superfamily member 1A (Tumor necrosis factor receptor 1) (TNF-R1) (Tumor necrosis factor receptor type I) (TNF-RI) (TNFR-I) (p55) (p60) (CD antigen CD120a) [Cleaved into: Tumor necrosis factor receptor superfamily member 1A, membrane form; Tumor necrosis factor-binding protein 1 (TBPI)] TNF receptor superfamily member 1A Tumor necrosis factor receptor superfamily member 1A (Tumor necrosis factor receptor 1) (Tumor necrosis factor receptor type I) (p55) (p60) Tumor necrosis factor receptor superfamily member 1A |
Synonyms | TNFAR TNFR1 |
Description | FUNCTION: Receptor for TNFSF2/TNF-alpha and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. |
Accessions | ENST00000539372.5 F5H4T5 F5GWJ4 J9PH39 ENST00000543048.5 ENST00000437813.8 [P19438-5] ENST00000440083.7 ENST00000540022.5 F5H8A6 Q6Y4Q7 ENST00000698339.1 [P19438-5] F5H6Z2 ENST00000162749.7 [P19438-1] A0A8V8TLL5 F5H7N1 ENST00000536194.1 ENST00000535958.2 ENST00000534885.5 P19438 F5H6V7 ENST00000698340.1 [P19438-4] ENST00000543995.5 F5H061 |